iData Insights

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015 Is Released

Press Release   •   Jan 25, 2016 12:32 IST

it Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015 Summary Global Markets Direct s, Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD)s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Attention Deficit Hyperactivity Disorder (ADHD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @

To Get Sample Copy of Report visit @

Table of Contents

Introduction 7

Global Markets Direct Report Coverage 7

Attention Deficit Hyperactivity Disorder (ADHD) Overview 8

Therapeutics Development 9

Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview 9

Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis 10

Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies 11

Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes 15

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies 20

Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes 24

Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development 25

Alcobra Ltd 25

Amarantus Bioscience Holdings, Inc. 26

APeT Holding BV 27

Arbor Pharmaceuticals, LLC. 28

BCWorld Pharm Co. Ltd. 29

Collegium Pharmaceutical, Inc. 30

Curemark, LLC 31

Domain Therapeutics SA 32

DURECT Corporation 33

H. Lundbeck A/S 34

Heptares Therapeutics Limited 35

Highland Therapeutics, Inc. 36

Hisamitsu Pharmaceutical Co., Inc. 37

Integrative Research Laboratories Sweden AB 38

Intra-Cellular Therapies, Inc. 39

KemPharm, Inc. 40

Luc Therapeutics, Inc. 41

Medgenics Inc. 42

Merck & Co., Inc. 43

Neos Therapeutics, Inc. 44

NeuroDerm Ltd. 45

Neurovance, Inc. 46

P2D Bioscience 47

Polleo Pharma Limited 48

Reviva Pharmaceuticals Inc. 49

Samyang Biopharmaceuticals Corporation 50

Shire Plc 51

Signature Therapeutics, Inc 52

Sunovion Pharmaceuticals Inc. 53

Supernus Pharmaceuticals, Inc. 54

Taisho Pharmaceutical Holdings Co., Ltd. 55

Tris Pharma, Inc. 56

Vernalis Plc 57

Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment 58

Assessment by Monotherapy Products 58

Assessment by Combination Products 59

Assessment by Target 60

Assessment by Mechanism of Action 63

Assessment by Route of Administration 65

Assessment by Molecule Type 67

Drug Profiles 69

(nicotine + opipramol hydrochloride) - Drug Profile 69

amfetamine XR - Drug Profile 70

AR-08 - Drug Profile 71

BCWPE-003 - Drug Profile 72

BLI-1008 - Drug Profile 73

BNC-375 - Drug Profile 74

CB-8411 - Drug Profile 75

centanafadine IR - Drug Profile 76

centanafadine SR - Drug Profile 77

CM-4612 - Drug Profile 78

CTX-1301 - Drug Profile 79

CTX-1302 - Drug Profile 80

dasotraline - Drug Profile 81

dextroamphetamine - Drug Profile 83

dextroamphetamine MR - Drug Profile 84

eltoprazine - Drug Profile 85

etiguanfacine - Drug Profile 87

guanfacine hydrochloride ER - Drug Profile 88

histamine dihydrochloride - Drug Profile 90

HTL-1071 - Drug Profile 91

IRL-752 - Drug Profile 92

ITI-214 - Drug Profile 93

KP-415 CR - Drug Profile 94

lisdexamfetamine dimesylate - Drug Profile 96

Metadoxine ER - Drug Profile 100

methylphenidate hydrochloride - Drug Profile 102

methylphenidate hydrochloride - Drug Profile 103

methylphenidate hydrochloride MR - Drug Profile 104

methylphenidate hydrochloride SR - Drug Profile 106

methylphenidate hydrochloride XR - Drug Profile 107

MGS-0028 - Drug Profile 108

molindone hydrochloride ER - Drug Profile 109

NFC-1 - Drug Profile 110

niacinamide CR - Drug Profile 111

NT-0201 - Drug Profile 112

P-001 - Drug Profile 113

PBF-509 - Drug Profile 114

PD-2005 - Drug Profile 116

PD-2007 - Drug Profile 117

PFR-08001 - Drug Profile 118

PFR-8026 - Drug Profile 119

RP-5063 - Drug Profile 120

SHP-465 - Drug Profile 121

Small Molecules for Attention Deficit Hyperactivity Disorder - Drug Profile 122

Small Molecules to Agonize GPR88 for Attention Deficit Hyperactivity Disorder and Schizophrenia - Drug Profile 123

Small Molecules to Agonize NMDA2D for ADHD - Drug Profile 124

Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 125

Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD - Drug Profile 126

Small Molecules to Modulate Choline Transporter for ADHD - Drug Profile 127

TRI-102 - Drug Profile 128

V-81444 - Drug Profile 129

viloxazine hydrochloride - Drug Profile 130

vortioxetine hydrobromide - Drug Profile 131

VU-0238429 - Drug Profile 134

Attention Deficit Hyperactivity Disorder (ADHD) - Recent Pipeline Updates 135

Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects 170

Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products 175

Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones 176

Featured News & Press Releases 176

Appendix 183

Methodology 183

Coverage 183

Secondary Research 183

Primary Research 183

Expert Panel Validation 183

Contact Us 183

Disclaimer 184

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects